Live Terminal | Security Analysis of PHIL.MI
TERMINAL beta
Version: 0.1
Timestamp: 1708864849.611787
Options
100220.KS
52.83%
1809.TW
51.88%
006220.KS
49.51%
0756.HK
49.35%
B7J.DE
48.43%
0T8B.F
-39.43%
009310.KS
-40.63%
SZGPF
-42.69%
GOLL4.SA
-52.40%
HGEN.L
-53.60%
AAPL $182.88 -0.81%
AMD $176.41 -3.00%
AMZN $174.58 0.00%
BRK-B $417.87 0.65%
GOOG $145.44 0.08%
IBM $185.76 0.84%
INTC $43.28 0.71%
JNJ $161.87 0.89%
JPM $184.12 0.57%
META $488.06 0.40%
MSFT $410.31 -0.33%
O $53.27 0.85%
TSLA $195.04 -1.20%
WMT $176.24 0.47%
QQQ $436.78 -0.2945%
TLT $93.87 1.3387%
VUSA.DE $89.31 0.4025%
VUAA.DE $88.65 0.3918%
FJPR.L $5.64 1.5565%
VWRP.L $97.83 0.1638%
VWRL.L $98.54 0.1626%
EMGU.L $3.60 -0.1111%
RDVY $52.42 0.3446%
FLOT $50.98 0.0000%
SCHZ $45.74 0.4171%
IBB $138.19 0.7436%
C020.DE $21.34 0.0000%
DFAX $24.72 0.0810%
LYP6.DE $226.20 0.4440%
MEUD.PA $226.19 0.4173%
IDWR.L $71.10 0.4521%
IQQW.DE $65.72 0.3972%
EXS1.DE $145.70 0.2477%
XESC.L $6865.00 0.1240%
DFAU $35.25 0.0852%
ACWV $104.02 0.2602%
VHYD.L $63.92 0.2746%
VGWD.DE $59.24 0.5602%
FXKZ.ME $303.00 0.0000%

Latest articles

No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.

Sentiment statistics ?
PHIL.MI
μ null
null
null

Financial Histories

Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.

Overview
PHIL.MI
Latest Performance
PHIL.MI$18.15
$0.70 • 4.01%
PHIL.MI
Price 18.15
Change Pct 4.01
Change Abs 0.70
Market Cap 526.2 million
Eps 0.01
Pe Ratio 1815.00
Outstanding Shares 29.0 million
Volume 8785
Avg Volume 15249
Industry Biotechnology
Sector Name Health Care
Country Short Name IT
Announcement Earnings 2023-11-07 18:00:00+00:00
All metrics in USD or %.
Dividends

There is no dividend data to display. Refer our Dividend calendar for other accurate data.

Risk Profiles

Please sign up and become a member to view all risk profiles.

Competitors/Peer Groups

The peer analysis is for none of your tickers available

Focus

The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.

Company descriptions
PHIL.MI

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer.